ESR1 and cancer: Studies conducted on Withaferin A have noted the compound’s ability to target multiple oncogenic signaling pathways such as NF-κB, Akt, NOTCH, STAT3, and estrogen receptor α (ER-α); these pathways are often found active in human cancers (Vyas and Singh, 2014).